For Family and Friends

Caregiver NHL Resources

If someone you love has NHL, there are organizations and support groups for you. They can help you connect with others. They can also help you learn all you can about NHL. Below are some resources for caregivers. To see the full list of organizations and contact information, click here.

Cancer organizations

The Leukemia and Lymphoma Society

The Leukemia & Lymphoma Society (LLS): For Caregivers

Visit the caregiver section for the LLS site for information, tips, and resources to help lymphoma caregivers give and receive support.

Lymphoma Research Foundation

Lymphoma Research Foundation

The LRF site offers links to support programs that offer services for caregivers.

American Cancer Society (ACS)

American Cancer Society (ACS): Caregivers

Visit this page for quick links for caregivers within the ACS website.

National Cancer Institute (NCI)

National Cancer Institute (NCI): Coping with Cancer:
For Caregivers, Family, and Friends

Visit the NCI's caregiver's section. It includes information and advice to help you care for your friend or loved one and yourself.

Online NHL support

Cancer Survivors Network—American Cancer Society

csn.cancer.org
1-800-ACS-2345 (1-800-227-23451-800-227-2345)

CancerCare, Inc.

www.cancercare.org
1-800-813-HOPE (1-800-813-46731-800-813-4673)

Cancer Support Community

www.cancersupportcommunity.org
1-888-793-WELL (1-888-793-93551-888-793-9355)

Daily Strength

www.dailystrength.org

Genentech and Biogen Idec are not affiliated with any of these organizations. The information provided by Genentech, Biogen Idec, or these organizations is meant for informational purposes only. It is not meant to replace your physician's medical advice.

Next Section Caring for Yourself

Indications

RITUXAN® (Rituximab) is indicated for the treatment of patients with:

  • Previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to RITUXAN in combination with chemotherapy, as single-agent maintenance therapy
  • Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
  • Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
  • Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent

People with serious infections should not receive RITUXAN.

Important Safety Information

  • RITUXAN can cause serious side effects that can lead to death, including infusion reactions, tumor lysis syndrome (TLS; kidney failure due to fast breakdown of cancer cells), severe skin and mouth reactions, and progressive multifocal leukoencephalopathy (PML; a rare, serious brain infection).
  • RITUXAN has also been associated with serious and life-threatening side effects, including the return of active hepatitis B virus infection with sudden and serious liver problems including liver failure, and death, other serious infections that can lead to death, heart problems, kidney problems, and stomach and serious bowel problems including blockage and tears in the bowel that can sometimes lead to death.
  • The most common side effects of RITUXAN seen in patients with non-Hodgkin's lymphoma were infusion reactions, fever, chills, low white blood cells, infections, body aches, and tiredness. Before starting treatment with RITUXAN it is important to talk to your doctor about your medical history.
  • Tell your doctor about any side effect that bothers you or that does not go away. These are not all of the possible side effects with RITUXAN. For more information, ask your doctor.

Please see full Prescribing Information, including Medication Guide.

CVP=cyclophosphamide, vincristine, and prednisone or prednisolone; CHOP=cyclophosphamide, doxorubicin, vincristine, and prednisone.